D. E. Shaw & Co. Inc. Raises Position in OptimizeRx Co. (NASDAQ:OPRX)

D. E. Shaw & Co. Inc. grew its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 12.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 295,717 shares of the company's stock after purchasing an additional 32,062 shares during the period. D. E. Shaw & Co. Inc. owned approximately 1.61% of OptimizeRx worth $1,437,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new position in shares of OptimizeRx in the 4th quarter valued at $25,000. SG Americas Securities LLC acquired a new position in shares of OptimizeRx in the 4th quarter valued at $51,000. Wells Fargo & Company MN increased its position in shares of OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after acquiring an additional 2,797 shares during the period. BNP Paribas Financial Markets increased its position in shares of OptimizeRx by 504.6% in the 4th quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock valued at $108,000 after acquiring an additional 18,618 shares during the period. Finally, Corton Capital Inc. acquired a new position in shares of OptimizeRx in the 4th quarter valued at $110,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Trading Up 4.1%

OPRX stock opened at $12.09 on Friday. The company's 50-day simple moving average is $9.10 and its 200-day simple moving average is $6.66. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 52-week low of $3.78 and a 52-week high of $13.19. The firm has a market cap of $223.60 million, a P/E ratio of -9.09 and a beta of 1.28.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The business had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. As a group, equities analysts forecast that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.

Insider Transactions at OptimizeRx

In other news, Director James Paul Lang bought 321,408 shares of the stock in a transaction dated Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the purchase, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 5.60% of the company's stock.

Analyst Upgrades and Downgrades

OPRX has been the topic of several research reports. B. Riley reissued a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Citigroup reissued an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. JMP Securities upped their target price on OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research report on Tuesday, May 13th. Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Wall Street Zen raised OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $10.38.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.